AstraZeneca PLC develops and commercializes prescription medicines across oncology, rare diseases, and BioPharmaceuticals, including cardiovascular, renal and metabolism, respiratory, and immunology. News about AZN commonly covers clinical-trial results, FDA and advisory-committee actions, product approvals, and updates to marketed medicines such as TRUQAP, BREZTRI, SAPHNELO, IMFINZI, IMJUDO, and ULTOMIRIS.
Company updates also address quarterly revenue and earnings trends, alliance and collaboration revenue, licensing transactions for pipeline assets, and governance changes. Recurring development themes include targeted oncology, COPD, asthma, systemic lupus erythematosus, liver cancer, prostate cancer, and rare or immune-mediated diseases.
AstraZeneca (AZN) opened a new global research and development center in Kendall Square, Cambridge, Massachusetts, expanding its research presence in the state.
The opening accompanies an investment of more than $1 billion in Massachusetts, part of its broader $50 billion US investment. AstraZeneca expects the Massachusetts investment to expand its workforce in the state by over 50 percent in the coming years. Together with its genomic medicine site at 100 Binney Street, the new center will house nearly 2,000 researchers and scientists. The 570,000-square-foot facility will support work on oncology, cell therapy, chronic disease and rare disease medicines.
Summit Therapeutics (SMMT) closed AstraZeneca’s (AZN) $2.0 billion equity investment to support development of its investigational cancer therapy ivonescimab.
AstraZeneca purchased approximately 108,955 preferred shares, convertible into Summit common shares at a 1:1,000 ratio. The implied common share price of $18.36 represents a premium to the closing trading price on the investment’s announcement day. Summit plans to use the funds to accelerate development across solid tumors, including combinations with sonesitatug vedotin and Datroway, drugs that deliver chemotherapy through antibodies. The FDA accepted Summit’s ivonescimab marketing application for filing in January 2026, with a target decision date of November 14, 2026.
Summit Therapeutics (SMMT) announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab combinations. The agreement covers ivonescimab with Datroway (datopotamab deruxtecan), an antibody linked to a cancer drug that targets TROP2. The companies intend to evaluate the combination across multiple solid tumor settings, including breast and lung cancer, starting with a Phase III trial in first-line triple-negative breast cancer.
AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will supply its respective therapy and contribute to trial costs, while retaining development and commercial rights to its own medicine. Ivonescimab remains investigational and is not approved in Summit’s licensed territories, including the United States and Europe.
Daiichi Sankyo (4568) and AstraZeneca (AZN) entered a clinical trial collaboration with Summit Therapeutics (SMMT) to evaluate Datroway combined with ivonescimab.
The collaboration covers multiple tumor types, including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer, testing the combination as an initial treatment. Datroway is an antibody-drug conjugate, which links an antibody to a cancer-killing drug, jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
Each company will supply its respective compound and contribute to trial costs. AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. Each company will retain development and commercial rights to its respective medicine. The agreement establishes planned combination studies; it does not report results from them.
Summit Therapeutics (SMMT) agreed to a $2 billion convertible preferred-share investment from AstraZeneca (AZN) alongside a signed cancer-trial collaboration.
AstraZeneca will buy approximately 108,955 preferred shares, convertible into Summit common stock at a 1:1,000 ratio. The conversion implies $18.36 per common share, a premium to the closing trading price and 10% above the prior week’s five-day volume-weighted average. Closing is expected by the end of the announcement week, subject to customary conditions.
The signed collaboration will test Summit’s investigational ivonescimab with AstraZeneca’s sonesitatug vedotin in gastrointestinal cancers. Both companies will supply their drugs and share study costs. A separate, non-binding memorandum outlines intended trials combining ivonescimab with other AstraZeneca cancer medicines, including antibody-drug conjugates.
AstraZeneca (AZN) received US Priority Review for an IMFINZI and enfortumab vedotin regimen in muscle-invasive bladder cancer.
The FDA accepted a supplemental Biologics License Application for IMFINZI (durvalumab) given around surgery with enfortumab vedotin given before surgery. The application covers patients who are ineligible for or have declined cisplatin-based chemotherapy. AstraZeneca anticipates an FDA decision in the fourth quarter of 2026; Priority Review is not an approval.
In a planned interim analysis of the VOLGA Phase III trial, the regimen showed statistically significant improvements in event-free survival and overall survival against bladder-removal surgery with or without approved treatment after surgery. Safety was consistent with the known profiles of the two medicines, with no new safety signals identified. Results will be presented at a forthcoming medical meeting.
AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu has received a positive CHMP opinion in the EU as adjuvant monotherapy for adults with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted therapy.
The recommendation is based on phase 3 DESTINY-Breast05, where Enhertu reduced the risk of invasive disease recurrence or death (IDFS) by 53% versus T-DM1 (HR=0.47; 95% CI: 0.34-0.66; p<0.0001). Three-year IDFS was 92.4% with Enhertu versus 83.7% with T-DM1. Disease-free survival was also improved, with a 53% risk reduction and three-year DFS of 92.3% vs 83.5%. The safety profile was consistent with prior experience; ILD/pneumonitis occurred in 9.6% of patients (mostly low grade), including 0.2% grade 5 events. The CHMP opinion now goes to the European Commission for final marketing authorization decision.
AstraZeneca (AZN) reported that ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improved progression-free survival versus pembrolizumab plus platinum-pemetrexed chemotherapy as 1st-line therapy for unresectable, locally advanced or metastatic HER2-mutant non-squamous NSCLC in the Phase III DESTINY-Lung04 trial.
ENHERTU monotherapy reduced the risk of disease progression or death by 37.0% (HR 0.63; 95% CI 0.50-0.79; p<0.0001), with median PFS of 14.3 months versus 8.3 months for pembrolizumab plus chemotherapy (BICR). Objective response rate was 70.0% (159/227) for ENHERTU versus 44.5% (101/227) for the control arm, and median duration of response was 13.4 vs 9.7 months. Median PFS2 was 22.7 vs 17.3 months (HR 0.80; 95% CI 0.62-1.02).
Median overall survival was 29.3 months with ENHERTU and 33.1 months with pembrolizumab plus chemotherapy (HR 1.15; 95% CI 0.88-1.52), with OS data 46.9% mature and not formally tested. Grade ≥3 treatment-related adverse events were similar (34.1% vs 33.6%), but ILD/pneumonitis occurred in 20.8% of ENHERTU-treated patients, including Grade 5 events.
AstraZeneca (AZN) reported eight-year overall survival data from the Phase III ADAURA trial showing sustained benefit of TAGRISSO (osimertinib) versus placebo in early-stage EGFR‑mutated NSCLC after complete tumor resection.
In the primary population (stages II‑IIIA), TAGRISSO reduced the risk of death by 47% versus placebo (HR 0.53; 95% CI 0.38‑0.75), with an estimated 74% of patients alive at 96 months compared to 58% on placebo. In the overall population (stages IB‑IIIA), the risk of death was reduced by 48% (HR 0.52; 95% CI 0.39‑0.71), with 79% versus 64% alive at eight years. Median follow‑up reached 92 and 93.3 months for TAGRISSO in the primary and overall populations, respectively. Final ADAURA safety remained consistent with the established profile, while extensive safety information highlights key risks including ILD/pneumonitis, QTc prolongation, cardiomyopathy, ocular and severe cutaneous reactions, and aplastic anemia.
AstraZeneca (AZN) and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) achieved a median progression‑free survival (PFS) of 14.3 months as first‑line therapy for patients with unresectable, locally advanced or metastatic HER2 mutant non‑squamous non‑small cell lung cancer in the phase 3 DESTINY‑Lung04 trial, versus 8.3 months with pembrolizumab plus platinum‑pemetrexed chemotherapy (HR=0.63; p<0.0001).
Enhertu reduced the risk of disease progression or death by 37.0% and showed an objective response rate of 70.0% compared with 44.5% for the control arm. Median duration of response was 13.4 months with Enhertu versus 9.7 months, and median PFS2 was 22.7 months versus 17.3 months. Overall survival data were 46.9% mature; median OS was 29.3 months with Enhertu and 33.1 months with pembrolizumab plus chemotherapy (HR=1.15), with no observed OS benefit at this interim analysis.
Grade ≥3 treatment‑related adverse events occurred in 34.1% of Enhertu patients. Interstitial lung disease or pneumonitis was seen in 20.8% of patients, including 1.8% grade 5 events.